INDV
Get informed when a big investor buys or sells
+ FollowOvervalued by 103.6% based on the discounted cash flow analysis.
| Market cap | $4.35 Billion |
|---|---|
| Enterprise Value | $4.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.68 |
| Beta | 1.03 |
| Outstanding Shares | 125,352,000 |
| P/E Ratio | 12.28 |
|---|---|
| PEG | 13.74 |
| Price to Sales | 3.51 |
| Price to Book Ratio | -17.53 |
| Enterprise Value to Revenue | 3.29 |
| Enterprise Value to EBIT | 12.5 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3684▼ 50.46% |
|---|---|
| Total Calls | 2,401,500▲ 672.43% |
| Total Puts | 884,600▲ 225.94% |
Holdings and activity of institutional investors.
| Ownership % | 101.65%▼ 0.53% |
|---|---|
| Total Invested | $5.14B▲ 32.20% |
| Investors Holding | 347▲ 51.00% |
No data
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...